Israel Englander Relay Therapeutics, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 2,942,875 shares of RLAY stock, worth $9.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,942,875

Previous 2,568,384 14.58%

Holding current value

$9.86 Million

Previous $10.6 Million 27.13%

% of portfolio

0.0%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$2.62 - $4.92 $981,166 - $1.84 Million	374,491 Added 14.58%	2,942,875 $7.71 Million
Q4 2024 Feb 14, 2025	BUY	$4.12 - $6.8 $6.22 Million - $10.3 Million	1,508,777 Added 142.39%	2,568,384 $10.6 Million
Q3 2024 Nov 14, 2024	SELL	$6.23 - $9.51 $558,021 - $851,810	-89,570 Reduced 7.79%	1,059,607 $7.5 Million
Q2 2024 Aug 14, 2024	BUY	$5.9 - $8.02 $5.44 Million - $7.39 Million	921,271 Added 404.23%	1,149,177 $7.49 Million
Q1 2024 May 15, 2024	BUY	$7.5 - $12.07 $307,050 - $494,145	40,940 Added 21.9%	227,906 $1.89 Million
Q4 2023 Feb 14, 2024	SELL	$6.01 - $11.48 $8.34 Million - $15.9 Million	-1,387,191 Reduced 88.12%	186,966 $2.06 Million
Q2 2023 Aug 14, 2023	BUY	$9.99 - $18.27 $15.7 Million - $28.8 Million	1,574,157 New	1,574,157 $19.8 Million
Q4 2022 Feb 14, 2023	BUY	$14.16 - $24.02 $7.57 Million - $12.8 Million	534,902 Added 1329.48%	575,136 $8.59 Million
Q3 2022 Nov 14, 2022	SELL	$18.07 - $31.37 $2.63 Million - $4.56 Million	-145,323 Reduced 78.32%	40,234 $900,000

Others Institutions Holding RLAY

# of Institutions

224

Shares Held

159M

Call Options Held

153K

Put Options Held

49.2K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $403M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account